Citations

Clear

9383 citation(s) found for "Thomas, PS".

Endovascular Thrombectomy With and Without Preceding Thrombolysis in Posterior Circulation Stroke—Insights From STAR
Heide, Ev‐Christin , Brinjikji, Waleed , Chowdhry, Shakeel , Dumont, Travis M., Ernst, Marielle , Ezzeldin, Mohamad , Kan, Peter, Kim, Joon‐Tae , Moss, Mark, Polifka, Adam , Psychogios, Marios‐Nikos , Rai, Ansaar , Starke, Robert M. , Tanweer, Omar , Williamson, Richard A., Spiotta, Alejandro M , Maier, Ilko , Investigators, STAR, Kasab, Sami Al , Alawieh, Ali , Arthur, Adam Stephen , Crosa, Roberto , Cuellar, Hugo , Leacy, Reade De , Fragata, Isabel , Howard, Brian M , Jabbour, Pascal , Levitt, Michael R. , Mascitelli, Justin R , Matouk, Charles , Navía, Pedro , Osbun, Joshua W , Park, Min S. , Romano, Daniele G., Shaban, Amir , Williamson, Richard, Wolfe, Stacey Q , Yoshimura, Shinichi , Investigators, STAR

Mayo Clinic

Stroke: Vascular and Interventional Neurology | July 16, 2024 | Volume: 4 | Issue: 5 | Pages: No page available

10.1161/svin.124.001334 | PMID 41586281 Get It

Background Multiple randomized trials could not establish the noninferiority of endovascular thrombectomy (EVT) alone without preceding intravenous thrombolysis (IVT) or superiority of IVT followed by EVT in anterior circulation large‐vessel occlusion stroke. The role of prior IVT in posterior circulation large‐vessel occlusion remains controversial. Methods In this multicenter, retrospective study, patients with stroke with large‐vessel occlusion in the posterior circulation who received EVT alone or with IVT were selected from the stroke thrombectomy and aneurysm registry between 2013 and 2022. Effects of IVT followed by thrombectomy on favorable functional outcome (defined as modified Rankin scale≤3 at 90 days) and safety were investigated using multivariable logistic and linear regression models. Results Of the 588 included patients, 67% (n = 394) were treated with EVT alone and 29% (n = 170) with EVT after IVT, and 4% (n = 24) have missing values on this variable. Controlling for multiple confounding factors, IVT was not associated with a higher likelihood of favorable functional outcome at 90 days (odds ratio, 1.04 [95% CI, 0.52–2.09; P = 0.901). Thrombectomy alone did not show any safety advantages compared with those receiving IVT. Conclusion Similar functional outcomes and complication rates were seen in patients with posterior circulation large‐vessel occlusion treated with EVT alone versus EVT after IVT. Further prospective studies are required to determine the utility of IVT in posterior circulation stroke, especially in patients being directly admitted to thrombectomy centers.
A multifaceted ecological approach to explore links between environmental factors and the epidemiology of disorders of gut–brain interaction
Fairlie, Thomas, Shah, Ayesha, Fang, Xiucai , Ghoshal, Uday C. , Kashyap, Purna , Mulak, Agata , Lee, Yeong Yeh , Jones, Michael , Holtmann, Gerald , Fang, Xiucai , Ghoshal, Uday C , Kashyap, Purna C , Mulak, Agata , Lee, Yeong Yeh , Sperber, Ami D , Talley, Nicholas J. , Jones, Michael P , Holtmann, Gerald J , Shah, Ayesha , Wong, Reuben K. , Koloski, Natasha , Moy, Naomi , Talley, Nicholas J.

Mayo Clinic

Neurogastroenterology & Motility | July 15, 2024 | Volume: 36 | Issue: 9 | Pages: No page available

10.1111/nmo.14866 | PMID 39005136 Get It

AbstractBackgroundDisorders of gut–brain interaction (DGBI) are characterized by debilitating symptoms not explained by structural or biochemical abnormalities. While functional conditions present with complex, likely heterogeneous pathophysiology, we aimed to investigate if proxy measures of sociocultural and environmental factors are associated with the prevalence of various DGBI in populations across the world.MethodsWe performed an ecological study utilizing peer‐reviewed published datasets reporting for 26 countries prevalence rates of DGBI (Rome Foundation Global Epidemiology Study, RFGES), with six independent variables: Helicobacter pylori prevalence and household size as proxy measures for orofecal infections, gross domestic product per capita (GDP), and median age as a proxy measures for socioeconomic development, density of fast food outlets (FFO) per 100,000 population as proxy measure for processed food exposure, and suicide mortality rate per 100,000 people, and world happiness scores were used as a proxy for psychological stress. The data were retrieved from publicly accessible datasets (United Nations, CIA World Factbook, World Bank, World Happiness Report, commercial/financial reports of a global FFO chain). We used linear regression to assess variables in univariate and multivariate analysis and report standardized β coefficients with 95% confidence intervals (CI).Key ResultsThe regression model revealed that the overall prevalence of DGBI was inversely associated with both GDP per capita (β = −0.57, 95% CI: −0.92, −0.22, p = 0.002) and happiness scores (β = −0.433 95% CI: 0.821, −0.065, p = 0.023), while being positively associated with H. pylori prevalence (β = 0.40, 95% CI: 0.008, 0.81, p = 0.046). The prevalence of functional constipation (FC) was also inversely associated with GDP per capita (β = −0.50, 95% CI: −0.86, −0.13, p = 0.01) and happiness scores (β = −0.497, 95% CI: −0.863, −0.132, p = 0.01), while being positively associated with H. pylori prevalence (β = 0.53, 95% CI: 0.16, 0.91, p = 0.007). The Multivariate model analysis revealed that combining the factors of H. pylori prevalence, suicide rate, household size and happiness scores showed statistically significant association with FC (p = 0.039). Household size (β = −0.43, 95% CI: −0.82, 0.038, p = 0.033) and suicide rates (β = 0.55, 95% CI: 0.19, 0.90, p = 0.004) were statistically significantly associated with functional diarrhea. Irritable bowel syndrome (IBS) was associated with GDP per capita (β = −0.40, 95% CI: −0.79, −0.014, p = 0.043) and happiness scores (β = −0.390, 95% CI: −0.778, −0.003, p = 0.049).Conclusions & InferencesUtilizing publicly available data, the prevalence of DGBI across diverse countries is linked to various socio‐cultural and environmental factors. Collectively, the data suggests that the prevalence of DGBI is increased in less prosperous regions of the world.
Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma
Witzig, Thomas E. , Sokol, Lubomir , Kim, Won Seog, Vicente, Fátima de la Cruz , Martı́n, Alejandro , Advani, Ranjana H. , Vidal, Jose Maria Roncero, Navarrete, Raquel De Oña, Izquierdo, Antonia Rodríguez, Domingo‐Doménech, Eva , Saunders, Andrew , Bendris, Nawal , Mackey, J., Leoni, Mollie , Witzig, T.E. , Advani, Ranjana H , Domingo-Domenech, Eva , Sokol, Lubomir , Marín‐Niebla, Ana , Terol, María José , Foss, Francine M. , García-Sancho, Alejandro Martín , Foss, Francine

Mayo Clinic

Blood Advances | July 11, 2024 | Volume: 8 | Issue: 17 | Pages: 4581-4592

10.1182/bloodadvances.2024012806 | PMID 38991123 Get It

Abstract A phase 2, international, open-label, nonrandomized, single-arm trial was conducted to evaluate the efficacy and safety of tipifarnib, a farnesyltransferase inhibitor, as monotherapy for relapsed/refractory peripheral T-cell lymphoma (PTCL) and to evaluate tumor mutation profile as a biomarker of response. Adults with relapsed/refractory PTCL received tipifarnib 300 mg orally twice daily for 21 days in a 28-day cycle. The primary end point was objective response rate (ORR); secondary end points included ORR, progression-free survival (PFS), duration of response (DOR), and adverse events (AEs) in specific subtypes. Sixty-five patients with PTCL were enrolled: n = 38 angioimmunoblastic T-cell lymphoma (AITL), n = 25 PTCL not otherwise specified, and n = 2 other T-cell lymphomas. The ORR was 39.7% (95% confidence interval [CI], 28.1-52.5) in all patients and 56.3% (95% CI, 39.3-71.8) for AITL. Median PFS was 3.5 months overall (954% CI, 2.1-4.4), and 3.6 months (95% CI, 1.9-8.3) for AITL. Median DOR was 3.7 months (95% CI, 2.0-15.3), and greatest in patients with AITL (7.8 months; 95% CI, 2.0-16.3). The median overall survival was 32.8 months (95% CI, 14.4 to not applicable). Tipifarnib-related hematologic AEs were manageable and included neutropenia (43.1%), thrombocytopenia (36.9%), and anemia (30.8%); other tipifarnib-related AEs included nausea (29.2%) and diarrhea (27.7%). One treatment-related death occurred. Mutations in RhoA, DNMT3A, and IDH2 were seen in 60%, 33%, and 27%, respectively, in the AITL tipifarnib responder group vs 36%, 9%, and 9% in the nonresponder group. Tipifarnib monotherapy demonstrated encouraging clinical activity in heavily pretreated relapsed/refractory PTCL, especially in AITL, with a manageable safety profile. This trial was registered at www.ClinicalTrials.gov as #NCT02464228.
Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL
Khurana, Arushi , Mwangi, Raphael , Nastoupil, Loretta J. , Farooq, Umar , Romancik, Jason T. , McDonnell, Timothy J. , Riska, Shaun M., Lossos, lzidore S., Martin, Peter W., Flowers, Christopher R. , Nowakowski, Grzegorz S. , Farooq, Umar , Romancik, Jason T , Lossos, Izidore S , Witzig, T.E. , Cerhan, James R , Maurer, Matthew , Nastoupil, Loretta J , Reagan, Patrick Michael , Kahl, Brad S. , Martin, Peter, Witzig, Thomas E. , Cerhan, James R. , Maurer, Matthew J.

Mayo Clinic

Blood Advances | July 11, 2024 | Volume: 8 | Issue: 16 | Pages: 4414-4422

10.1182/bloodadvances.2024012838 | PMID 38991126 Get It

Abstract Underrepresentation of racial and ethnic subgroups in cancer clinical trials remains a persistent challenge. Restrictive clinical trial eligibility criteria have been shown to exacerbate this problem. We previously identified that up to 24% of patients treated with standard immunochemotherapy would have been excluded from recent first-line trials in diffuse large B-cell lymphoma (DLBCL) based on 5 laboratory-based criteria. These ineligible patients had worse clinical outcomes and increased deaths related to lymphoma progression, suggesting the potential exclusion of patients who could have benefited most from the novel therapies being evaluated. Using data from the prospectively enrolled Lymphoma Epidemiology Outcomes cohort study, with demographics broadly similar to the US patients diagnosed with lymphoma, we evaluated the impact of laboratory eligibility criteria from recent first-line DLBCL trials across various racial and ethnic backgrounds. There were significant differences in the baseline laboratory values by race/ethnicity with Black/African American (AA) patients having the lowest mean hemoglobin and highest creatinine clearance. Based on recent clinical trial eligibility criteria, AA and Hispanic patients had higher rates of laboratory-based ineligibility than non-Hispanic White patients. The largest gap in the clinical outcomes between eligible and noneligible patients was noted within AA patients with an overall survival hazard ratio based on POLARIX clinical trial criteria of 4.09 (95% confidence interval, 1.83-9.14). A thoughtful approach to the utility of each criterion and cutoffs for eligibility needs to be evaluated in the context of its differential impact across various racial/ethnic groups.
Identification of ChatGPT‐Generated Abstracts Within Shoulder and Elbow Surgery Poses a Challenge for Reviewers
Stadler, Ryan D. , Sudah, Suleiman Y. , Denard, Patrick J. , Duralde, Xavier A. , Garrigues, Grant E. , Klifto, Christopher S. , Namdari, Surena , Sánchez‐Sotelo, Joaquín , Menendez, Mariano E. , Sanchez-Sotelo, Joaquin, Sanchez-Sotelo, J. , Denard, Patrick J , Moverman, Michael A. , Levy, Jonathan C., Menendez, Mariano E.

Mayo Clinic

Arthroscopy | July 9, 2024 | Volume: 41 | Issue: 4 | Pages: 916

10.1016/j.arthro.2024.06.045 | PMID 38992513 Get It

Purpose To evaluate the extent to which experienced reviewers can accurately discern between artificial intelligence (AI)–generated and original research abstracts published in the field of shoulder and elbow surgery and compare this with the performance of an AI detection tool. Methods Twenty‐five shoulder‐ and elbow‐related articles published in high‐impact journals in 2023 were randomly selected. ChatGPT was prompted with only the abstract title to create an AI‐generated version of each abstract. The resulting 50 abstracts were randomly distributed to and evaluated by 8 blinded peer reviewers with at least 5 years of experience. Reviewers were tasked with distinguishing between original and AI‐generated text. A Likert scale assessed reviewer confidence for each interpretation, and the primary reason guiding assessment of generated text was collected. AI output detector (0%‐100%) and plagiarism (0%‐100%) scores were evaluated using GPTZero. Results Reviewers correctly identified 62% of AI‐generated abstracts and misclassified 38% of original abstracts as being AI generated. GPTZero reported a significantly higher probability of AI output among generated abstracts (median, 56%; interquartile range [IQR], 51%‐77%) compared with original abstracts (median, 10%; IQR, 4%‐37%; P < .01). Generated abstracts scored significantly lower on the plagiarism detector (median, 7%; IQR, 5%‐14%) relative to original abstracts (median, 82%; IQR, 72%‐92%; P < .01). Correct identification of AI‐generated abstracts was predominately attributed to the presence of unrealistic data/values. The primary reason for misidentifying original abstracts as AI was attributed to writing style. Conclusions Experienced reviewers faced difficulties in distinguishing between human and AI‐generated research content within shoulder and elbow surgery. The presence of unrealistic data facilitated correct identification of AI abstracts, whereas misidentification of original abstracts was often ascribed to writing style. Clinical Relevance With rapidly increasing AI advancements, it is paramount that ethical standards of scientific reporting are upheld. It is therefore helpful to understand the ability of reviewers to identify AI‐generated content.
Accuracy and Precision of Acceleromyography, Electromyography, and Mechanomyography: Time to Rethink What We Know
Brull, Sorin J. , Fuchs‐Buder, Thomas , Brull, Sorin J

Mayo Clinic

Anesthesiology | July 9, 2024 | Volume: 141 | Issue: 2 | Pages: 204-207

10.1097/aln.0000000000005054 | PMID 38980163 Get It

2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson, Sindhu R. , Bernstein, Elana J. , Bolster, Marcy B. , George, Michael , Khanna, Dinesh , Aggarwal, Rohit , Allen, Aberdeen, Buckley, Lenore M. , Corwin, Douglas S., Dellaripa, Paul F. , Domsic, Robyn T. , Doyle, Tracy J. , Falardeau, Catherine Marie, Gibbons, Fiona K., Johnson, Cheilonda , Lim, Sian Yik , McMahan, Zsuzsanna H. , Merck, Samantha J. , Nesbitt, Kiana, Scholand, Mary Beth , Shapiro, Lee , Sharkey, Christine D., Summer, Ross , Varga, John , Warrier, Anil, Agarwal, Sandeep K. , Antin‐Ozerkis, Danielle, Chowdhary, Vaidehi , D’Amico, Jane E. Dematte, Hallowell, Robert W. , Hinze, Alicia M. , Injean, Patil, Jiwrajka, Nikhil , Joerns, Elena K. , Lee, Joyce , Natalini, Jake G. , Saygın, Didem , Lakin, Kimberly S. , Solomon, Joshua J. , Turgunbaev, Marat, Vaseer, Samera, Turner, Amy S. , Uhl, Stacey , Ivlev, Ilya , George, Michael , Khanna, Dinesh , Aggarwal, Rohit , Assassi, Shervin , Buckley, Lenore , Dellaripa, Paul F , Domsic, Robyn T , Frech, Tracy M , Hinchcliff, Monique , Lim, Sian Yik , McMahan, Zsuzsanna H , Hinze, Alicia M , Jiwrajka, Nikhil , Joerns, Elena K , McDermott, Gregory , Natalini, Jake G , Sparks, Jeffrey A , Turner, Amy S , Ivlev, Ilya , Bernstein, Elana J , Lee, Joyce S , Chung, Jonathan Hero , Danoff, Sonye Karen , Guyatt, Gordon , Mirza, Reza Donald , Assassi, Shervin , Chami, Hassan A. , Frech, Tracy , Kanne, Jeffrey P. , Kim, John S. , Matson, Scott M. , Bemiss, B. , Makol, Ashima , McDermott, Gregory C , Oldham, Justin M , Singh, Namrata , Sparks, Jeffrey A.

Mayo Clinic

Arthritis & Rheumatology | July 9, 2024 | Volume: 76 | Issue: 8 | Pages: 1182-1200

10.1002/art.42861 | PMID 38978310 Get It

Objective We provide evidence‐based recommendations regarding the treatment of interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases (SARDs). Methods We developed clinically relevant population, intervention, comparator, and outcomes questions. A systematic literature review was then performed, and the available evidence was rated using the Grading of Recommendations, Assessment, Development, and Evaluation methodology. A panel of clinicians and patients reached consensus on the direction and strength of the recommendations. Results Thirty‐five recommendations were generated (including two strong recommendations) for first‐line SARD‐ILD treatment, treatment of SARD‐ILD progression despite first‐line ILD therapy, and treatment of rapidly progressive ILD. The strong recommendations were against using glucocorticoids in systemic sclerosis–ILD as a first‐line ILD therapy and after ILD progression. Otherwise, glucocorticoids are conditionally recommended for first‐line ILD treatment in all other SARDs. Conclusion This clinical practice guideline presents the first recommendations endorsed by the American College of Rheumatology and American College of Chest Physicians for the treatment of ILD in people with SARDs.
Symptomatic intracerebral hemorrhage in proximal and distal medium middle cerebral artery occlusion patients treated with mechanical thrombectomy
Yedavalli, Vivek , Salim, Hamza , Musmar, Basel , Adeeb, Nimer, Essibayi, Muhammed Amir , Naamani, Kareem El , Henninger, Nils , Sundararajan, Sri Hari , Kuhn, Anna Luisa, Khalife, Jane, Tan, Benjamin YQ, Heit, Jeremy J. , Regenhardt, Robert W, Cancelliere, Nicole M , Rouchaud, Aymeric , Sheth, Sunil A, Puri, Ajit S, Dyzmann, Christian , Colasurdo, Marco , Barreau, Xavier, Renieri, Leonardo, Filipe, Joo Pedro, Harker, Pablo, Marotta, Thomas R. , Spears, Julian, Jabbour, Pascal , Biswas, Arundhati , Clarenon, Frdric, Varela, Ricardo, Baker, Amanda, Altschul, David , Gonzalez, Nestor R. , Mhlenbruch, Markus A, Costalat, Vincent, Gory, Benjamin, Stracke, Paul, Aziz-Sultan, Mohammad Ali, Shaikh, Hamza , Liebeskind, David S. , Pedicelli, Alessandro, Alexandre, Andrea M, Tancredi, Illario, Faizy, Tobias D, Kalsoum, Erwah, Lubicz, Boris, Patel, Aman B, Guenego, Adrien , Regenhardt, Robert W. , Tan, Benjamin Yong‐Qiang , Varela, Ricardo , Alexandre, Andrea , Pulli, Benjamin , Yedavalli, Vivek S , Salim, Hamza , ElNaamani, Kareem , Ghozy, Sherief , Scarcia, Luca , Cancelliere, Nicole M , Rouchaud, Aymeric , Fiehler, Jens , Colasurdo, Marco , Alexandru Radu, Răzvan , Ota, Takahiro , Jabbour, Pascal , Siegler, James E , Nguyen, Thanh N , Altschul, David J , Gonzalez, Nestor R , Hecker, Constantin , Shaikh, Hamza A , Liebeskind, David S. , Mendes Pereira, Vitor , Guenego, Adrien , Dmytriw, Adam A , Heit, Jeremy J , Musmar, Basel , Regenhardt, Robert W , Essibayi, Muhammed Amir , Henninger, Nils , Tan, Benjamin Yq , Alexandre, Andrea M , Pulli, Benjamin , Varela, Ricardo , Adeeb, Nimer , Kühn, Anna Luisa , Khalife, Jane , Ghozy, Sherief , Bernstock, Joshua D. , Fiehler, Jens , Sheth, Sunil A , Puri, Ajit S , Barreau, Xavier , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Spears, Julian , Mowla, Ashkan , Jabbour, Pascal , Siegler, James E. , Nguyen, Thanh N. , Baker, Amanda, Costalat, Vincent , Gory, Benjamin , Aziz‐Sultan, Mohammad Ali , Hecker, Constantin , Pedicelli, Alessandro , Tancredi, Illario , Faizy, Tobias D. , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Dmytriw, Adam A.

Mayo Clinic

Journal of NeuroInterventional Surgery | July 8, 2024 | Volume: 17 | Issue: 8 | Pages: 803-810

10.1136/jnis-2024-021879 | PMID 38977305 Get It

Background Acute ischemic stroke (AIS) caused by distal medium vessel occlusions (DMVOs) represents a significant proportion of overall stroke cases. While intravenous thrombolysis (IVT) has been a primary treatment, advancements in endovascular procedures have led to increased use of mechanical thrombectomy (MT) in DMVO stroke patients. However, symptomatic intracerebral hemorrhage (sICH) remains a critical complication of AIS, particularly after undergoing intervention. This study aims to identify factors associated with sICH in DMVO stroke patients undergoing MT. Methods This retrospective analysis utilized data from the Multicenter Analysis of Distal Medium Vessel Occlusions: Effect of Mechanical Thrombectomy (MAD-MT) registry, involving 37 centers across North America, Asia, and Europe. Middle cerebral artery (MCA) DMVO stroke patients were included. The primary outcome measured was sICH, as defined per the Heidelberg Bleeding Classification. Univariable and multivariable logistic regression were used to identify factors independently associated with sICH. Results Among 1708 DMVO stroke patients, 148 (8.7%) developed sICH. Factors associated with sICH in DMVO patients treated with MT included older age (adjusted odds ratio (aOR) 1.01, 95% confidence interval (95% CI) 1.00 to 1.03, P=0.048), distal occlusion site (M3, M4) compared with medium occlusions (M2) (aOR 1.71, 95% CI 1.07 to 2.74, P=0.026), prior use of antiplatelet drugs (aOR 2.06, 95% CI 1.41 to 2.99, P<0.001), lower Alberta Stroke Program Early CT Scores (ASPECTS) (aOR 0.75, 95% CI 0.66 to 0.84, P<0.001), higher preoperative blood glucose level (aOR 1.00, 95% CI 1.00 to 1.01, P=0.012), number of passes (aOR 1.27, 95% CI 1.15 to 1.39, P<0.001), and successful recanalization (Thrombolysis In Cerebral Infarction (TICI) 2b-3) (aOR 0.43, 95% CI 0.28 to 0.66, P<0.001). Conclusion This study provides novel insight into factors associated with sICH in patients undergoing MT for DMVO, emphasizing the importance of age, distal occlusion site, prior use of antiplatelet drugs, lower ASPECTS, higher preoperative blood glucose level, and procedural factors such as the number of passes and successful recanalization. Pending confirmation, consideration of these factors may improve personalized treatment strategies.
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson, Sindhu R. , Bernstein, Elana J. , Bolster, Marcy B. , George, Michael , Khanna, Dinesh , Aggarwal, Rohit , Allen, Aberdeen, Buckley, Lenore M. , Corwin, Douglas S., Dellaripa, Paul F. , Domsic, Robyn T. , Doyle, Tracy J. , Falardeau, Catherine Marie, Gibbons, Fiona K., Johnson, Cheilonda , Lim, Sian Yik , McMahan, Zsuzsanna H. , Merck, Samantha J. , Nesbitt, Kiana, Scholand, Mary Beth , Shapiro, Lee , Sharkey, Christine D., Summer, Ross , Varga, John , Warrier, Anil, Agarwal, Sandeep K. , Antin‐Ozerkis, Danielle, Chowdhary, Vaidehi , D’Amico, Jane E. Dematte, Hallowell, Robert W. , Hinze, Alicia M. , Injean, Patil, Jiwrajka, Nikhil , Joerns, Elena K. , Lee, Joyce , Natalini, Jake G. , Saygın, Didem , Lakin, Kimberly S. , Solomon, Joshua J. , Turgunbaev, Marat, Vaseer, Samera, Turner, Amy S. , Uhl, Stacey , Ivlev, Ilya , George, Michael , Khanna, Dinesh , Aggarwal, Rohit , Assassi, Shervin , Buckley, Lenore , Dellaripa, Paul F , Domsic, Robyn T , Frech, Tracy M , Hinchcliff, Monique , Lim, Sian Yik , McMahan, Zsuzsanna H , Hinze, Alicia M , Jiwrajka, Nikhil , Joerns, Elena K , McDermott, Gregory , Natalini, Jake G , Sparks, Jeffrey A , Turner, Amy S , Ivlev, Ilya , Bernstein, Elana J , Lee, Joyce S , Chung, Jonathan Hero , Danoff, Sonye Karen , Guyatt, Gordon , Mirza, Reza Donald , Assassi, Shervin , Chami, Hassan A. , Frech, Tracy , Kanne, Jeffrey P. , Kim, John S. , Matson, Scott M. , Bemiss, B. , Makol, Ashima , McDermott, Gregory C , Oldham, Justin M , Singh, Namrata , Sparks, Jeffrey A.

Mayo Clinic

Arthritis Care & Research | July 8, 2024 | Volume: 76 | Issue: 8 | Pages: 1051-1069

10.1002/acr.25348 | PMID 38973731 Get It

Objective We provide evidence‐based recommendations regarding the treatment of interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases (SARDs). Methods We developed clinically relevant population, intervention, comparator, and outcomes questions. A systematic literature review was then performed, and the available evidence was rated using the Grading of Recommendations, Assessment, Development, and Evaluation methodology. A panel of clinicians and patients reached consensus on the direction and strength of the recommendations. Results Thirty‐five recommendations were generated (including two strong recommendations) for first‐line SARD‐ILD treatment, treatment of SARD‐ILD progression despite first‐line ILD therapy, and treatment of rapidly progressive ILD. The strong recommendations were against using glucocorticoids in systemic sclerosis–ILD as a first‐line ILD therapy and after ILD progression. Otherwise, glucocorticoids are conditionally recommended for first‐line ILD treatment in all other SARDs. Conclusion This clinical practice guideline presents the first recommendations endorsed by the American College of Rheumatology and American College of Chest Physicians for the treatment of ILD in people with SARDs.
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson, Sindhu R. , Bernstein, Elana J. , Bolster, Marcy B. , George, Michael , Khanna, Dinesh , Aggarwal, Rohit , Allen, Aberdeen, Buckley, Lenore M. , Corwin, Douglas S., Dellaripa, Paul F. , Domsic, Robyn T. , Doyle, Tracy J. , Falardeau, Catherine Marie, Gibbons, Fiona K., Johnson, Cheilonda , Lim, Sian Yik , McMahan, Zsuzsanna H. , Merck, Samantha J. , Nesbitt, Kiana, Scholand, Mary Beth , Shapiro, Lee , Sharkey, Christine D., Summer, Ross , Varga, John , Warrier, Anil, Agarwal, Sandeep K. , Antin‐Ozerkis, Danielle, Chowdhary, Vaidehi , D’Amico, Jane E. Dematte, Hallowell, Robert W. , Hinze, Alicia M. , Injean, Patil, Jiwrajka, Nikhil , Joerns, Elena K. , Lee, Joyce S., Natalini, Jake G. , Saygın, Didem , Lakin, Kimberly S. , Solomon, Joshua J. , Turgunbaev, Marat, Vaseer, Samera, Turner, Amy S. , Uhl, Stacey , Ivlev, Ilya , George, Michael , Khanna, Dinesh , Aggarwal, Rohit , Assassi, Shervin , Buckley, Lenore , Dellaripa, Paul F , Domsic, Robyn T , Frech, Tracy M , Hinchcliff, Monique , Lim, Sian Yik , McMahan, Zsuzsanna H , Hinze, Alicia M , Jiwrajka, Nikhil , Joerns, Elena K , McDermott, Gregory , Natalini, Jake G , Sparks, Jeffrey A , Turner, Amy S , Ivlev, Ilya , Bernstein, Elana J , Chung, Jonathan Hero , Danoff, Sonye Karen , Guyatt, Gordon , Mirza, Reza Donald , Assassi, Shervin , Chami, Hassan A. , Frech, Tracy , Kanne, Jeffrey P. , Kim, John S. , Matson, Scott M. , Bemiss, B. , Makol, Ashima , McDermott, Gregory C , Oldham, Justin M , Singh, Namrata , Sparks, Jeffrey A.

Mayo Clinic

Arthritis Care & Research | July 8, 2024 | Volume: 76 | Issue: 8 | Pages: 1070-1082

10.1002/acr.25347 | PMID 38973729 Get It

ObjectiveWe provide evidence‐based recommendations regarding screening for interstitial lung disease (ILD) and the monitoring for ILD progression in people with systemic autoimmune rheumatic diseases (SARDs), specifically rheumatoid arthritis, systemic sclerosis, idiopathic inflammatory myopathies, mixed connective tissue disease, and Sjögren disease.MethodsWe developed clinically relevant population, intervention, comparator, and outcomes questions related to screening and monitoring for ILD in patients with SARDs. A systematic literature review was performed, and the available evidence was rated using the Grading of Recommendations, Assessment, Development, and Evaluation methodology. A Voting Panel of interdisciplinary clinician experts and patients achieved consensus on the direction and strength of each recommendation.ResultsFifteen recommendations were developed. For screening people with these SARDs at risk for ILD, we conditionally recommend pulmonary function tests (PFTs) and high‐resolution computed tomography of the chest (HRCT chest); conditionally recommend against screening with 6‐minute walk test distance (6MWD), chest radiography, ambulatory desaturation testing, or bronchoscopy; and strongly recommend against screening with surgical lung biopsy. We conditionally recommend monitoring ILD with PFTs, HRCT chest, and ambulatory desaturation testing and conditionally recommend against monitoring with 6MWD, chest radiography, or bronchoscopy. We provide guidance on ILD risk factors and suggestions on frequency of testing to evaluate for the development of ILD in people with SARDs.ConclusionThis clinical practice guideline presents the first recommendations endorsed by the American College of Rheumatology and American College of Chest Physicians for the screening and monitoring of ILD in people with SARDs.